$1.54
4.05% yesterday
Nasdaq, May 20, 07:46 pm CET
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Autolus Therapeutics plc Stock price

$1.53
+0.09 6.25% 1M
-1.27 45.36% 6M
-0.82 34.89% YTD
-2.49 61.94% 1Y
-1.21 44.16% 3Y
-9.94 86.66% 5Y
-23.47 93.88% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 3.38%
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Key metrics

Market capitalization $407.20m
Enterprise Value $200.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.23
P/S ratio (TTM) P/S ratio 45.19
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth -14.16%
Revenue (TTM) Revenue $9.01m
EBIT (operating result TTM) EBIT $-267.27m
Free Cash Flow (TTM) Free Cash Flow $-271.11m
Cash position $518.03m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 7.67
EV/Sales forward 3.77
Short interest 5.17%
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
100%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.01 9.01
14% 14%
100%
- Direct Costs 38 38
480% 480%
417%
-29 -29
807% 807%
-316%
- Selling and Administrative Expenses 96 96
125% 125%
1,066%
- Research and Development Expense 135 135
4% 4%
1,493%
-259 -259
54% 54%
-2,875%
- Depreciation and Amortization 8.19 8.19
27% 27%
91%
EBIT (Operating Income) EBIT -267 -267
53% 53%
-2,966%
Net Profit -238 -238
8% 8%
-2,643%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Positive
Seeking Alpha
about 18 hours ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
7 days ago
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have...
Neutral
Seeking Alpha
10 days ago
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants James Shin – Deutsche Bank Matthew Phipps – William Blair Karina Rabayeva – Truist Gil Blum – Needham & Company Yanan Zhu...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 647
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today